On this page

Cyclogyl

cyclopentolate hydrochloride · Solution/ Drops

Prescription ANDA TE AT RLD Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
Cyclogyl
Generic name
cyclopentolate hydrochloride
Dosage form
Solution/ Drops
Route
Ophthalmic
Marketing category
ANDA · ANDA
Labeler
Alcon Laboratories, Inc.
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
3
NDC product codes
3
Packages
6
Data completeness
76% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Cyclopentolate Hydrochloride 10 mg/mL 1298066 —
Cyclopentolate Hydrochloride 20 mg/mL 1298066 —
Cyclopentolate Hydrochloride 5 mg/mL 1298066 —

Forms, strengths and routes

Source: NDC Directory
Dosage form
Solution/ Drops
Route of administration
Ophthalmic
Presentations
9

Regulatory status

Source: Drugs@FDANDC Directory
Application number
084110
Application type
ANDA · Abbreviated New Drug Application
Approval date
July 31, 1974
Sponsor
ALCON LABS INC
Products on application
1
Submissions recorded
30
Products approved under application 084110.
Product Trade name Form Strength Ingredient Status TE Flags
084110-001 CYCLOGYL SOLUTION/DROPS CYCLOPENTOLATE HYDROCHLORIDE Prescription AT RLD RS

Therapeutic equivalence

Source: Orange Book
TE code
AT
Reference Listed Drug
Yes
Reference Standard
Yes

What this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 084110.
Type No. Action Status Date Review
Supplement 36 Labeling Approved October 31, 2003 —
Supplement 35 Manufacturing (CMC) Approved December 23, 2002 —
Supplement 34 Manufacturing (CMC) Approved October 11, 2002 —
Supplement 33 Manufacturing (CMC) Approved November 20, 2001 —
Supplement 31 Manufacturing (CMC) Approved April 28, 2000 —
Supplement 32 Manufacturing (CMC) Approved April 7, 2000 —
Supplement 29 Manufacturing (CMC) Approved May 7, 1999 —
Supplement 30 Manufacturing (CMC) Approved March 23, 1999 —
Supplement 27 Manufacturing (CMC) Approved March 4, 1999 —
Supplement 28 Manufacturing (CMC) Approved December 9, 1998 —
Supplement 26 Manufacturing (CMC) Approved February 17, 1998 —
Supplement 21 Labeling Approved January 16, 1997 —
Supplement 25 Manufacturing (CMC) Approved October 5, 1995 —
Supplement 24 Manufacturing (CMC) Approved August 4, 1995 —
Supplement 23 Manufacturing (CMC) Approved August 4, 1994 —
Supplement 22 Labeling Approved August 3, 1994 —
Supplement 20 Labeling Approved December 2, 1993 —
Supplement 17 Manufacturing (CMC) Approved June 4, 1993 —
Supplement 16 Manufacturing (CMC) Approved June 4, 1993 —
Supplement 19 Manufacturing (CMC) Approved November 5, 1992 —
Supplement 18 Labeling Approved July 29, 1992 —
Supplement 15 Manufacturing (CMC) Approved February 20, 1991 —
Supplement 14 Manufacturing (CMC) Approved February 20, 1991 —
Supplement 13 Labeling Approved October 13, 1989 —
Supplement 12 Labeling Approved August 28, 1989 —
Supplement 10 Manufacturing (CMC) Approved March 9, 1989 —
Supplement 9 Labeling Approved October 20, 1988 —
Supplement 4 Manufacturing (CMC) Approved December 8, 1983 —
Supplement 2 Manufacturing (CMC) Approved October 12, 1982 —
Original application 1 Approved July 31, 1974 —

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20240625). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20240625

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE: Cyclopentolate hydrochloride is used to produce mydriasis and cycloplegia.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION: Adults: Instill one or two drops of 0.5%, 1% or 2% solution in the eye which may be repeated in five to ten minutes if necessary. Complete recovery usually occurs in 24 hours. Complete recovery from mydriasis in some individuals may require several days. Children: Instill one or two drops of 0.5%, 1% or 2% solution in the eye which may be repeated five to ten minutes later by a second application of 0.5% or 1% solution if necessary. Small Infants: A single instillation of one drop of 0.5% in the eye. To minimize absorption, apply pressure over the nasolacrimal sac for two to three minutes. Observe infant closely for at least 30 minutes following instillation. Individuals with heavily pigmented irides may require higher strengths.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS: Should not be used if the patient is hypersensitive to any component of this preparation.

WARNINGS: FOR TOPICAL OPHTHALMIC USE ONLY . NOT FOR INJECTION. This preparation may cause Central Nervous System (CNS) disturbances. This is especially true in younger age groups, but may occur at any age, especially with the stronger solutions. Infants are especially prone to CNS and cardiopulmonary side effects from cyclopentolate. To minimize absorption, use only 1 drop of 0.5% CYCLOGYL solution per eye, followed by pressure applied over the nasolacrimal sac for two to three minutes. Observe infants closely for at least 30 minutes following instillation. Mydriatics may produce a transient elevation of intraocular pressure. Therefore, patients with untreated narrow angle glaucoma or anatomically narrow angles may be susceptible to angle closure following administration.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS: Ocular: Increased intraocular pressure, burning, photophobia, blurred vision, irritation, hyperemia, conjunctivitis, blepharoconjunctivitis, punctate keratitis, synechiae have been reported. Non-ocular: Use of cyclopentolate has been associated with psychotic reactions and behavioral disturbances, usually in children, especially with 2% concentration. These disturbances include ataxia, incoherent speech, restlessness, hallucinations, hyperactivity, seizures, disorientation as to time and place, and failure to recognize people. This drug produces reactions similar to those of other anticholinergic drugs, but the central nervous system manifestations as noted above are more common. Other toxic manifestations of anticholinergic drugs are skin rash, abdominal distention in infants, unusual drowsiness, tachycardia, hyperpyrexia, vasodilation, urinary retention, diminished gastrointestinal motility and decreased secretion in salivary and sweat glands, pharynx, bronchi and nasal passages. Severe manifestations of toxicity include coma, medullary paralysis and death.

Drug Interactions

openFDA Drug Labeling

Drug Interactions: Cyclopentolate may interfere with the ocular anti-hypertensive action of carbachol, pilocarpine, or ophthalmic cholinesterase inhibitors.

Description

openFDA Drug Labeling

Rx Only DESCRIPTION: CYCLOGYL ® (cyclopentolate hydrochloride ophthalmic solution, USP) is an anticholinergic prepared as a sterile, borate buffered, solution for topical ocular use. It is supplied in three strengths. The active ingredient is represented by the structural formula: Each mL of CYCLOGYL ® (cyclopentolate hydrochloride ophthalmic solution, USP) contains: Active: cyclopentolate hydrochloride 0.5%, 1% or 2%. Preservative: benzalkonium chloride 0.01%. Inactives: boric acid, edetate disodium, potassium chloride (except 2% strength), sodium carbonate and/or hydrochloric acid (to adjust pH), purified water. The pH range is between 3.0 and 5.5. chemical

OVERDOSAGE: Excessive dosage may produce behavioral disturbances, tachycardia, hyperpyrexia, hypertension, elevated intraocular pressure, vasodilation, urinary retention, diminished gastrointestinal motility and decreased secretion in salivary and sweat glands, pharynx, bronchi and nasal passages. Patients exhibiting signs of overdosage should receive supportive care and monitoring.

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED: In multiple-dose plastic DROP-TAINER® dispensers: 0.5% CYCLOGYL 1% CYCLOGYL 2% CYCLOGYL 15 mL NDC 0065-0395-15 2 mL NDC 0065-0396-02 2 mL NDC 0065-0397-02 5 mL NDC 0065-0396-05 5 mL NDC 0065-0397-05 15 mL NDC 0065-0396-15 15 mL NDC 0065-0397-15 Storage: Store at 8°C to 25°C (46°F to 77°F). After opening, Cyclogyl can be used until the expiration date on the bottle.

Adverse event reports

Source: openFDA FAERS
712
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: CYCLOPENTOLATE HYDROCHLORIDE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
0065-0395-15 0065-0395 Alcon Laboratories, Inc. 1 BOTTLE, PLASTIC in 1 CARTON (0065-0395-15) / 15 mL in 1 BOTTLE, PLASTIC October 15, 1975
0065-0396-02 0065-0396 Alcon Laboratories, Inc. 1 BOTTLE, PLASTIC in 1 CARTON (0065-0396-02) / 2 mL in 1 BOTTLE, PLASTIC October 15, 1975
0065-0396-05 0065-0396 Alcon Laboratories, Inc. 1 BOTTLE, PLASTIC in 1 CARTON (0065-0396-05) / 5 mL in 1 BOTTLE, PLASTIC October 15, 1975
0065-0397-02 0065-0397 Alcon Laboratories, Inc. 1 BOTTLE, PLASTIC in 1 CARTON (0065-0397-02) / 2 mL in 1 BOTTLE, PLASTIC October 15, 1975
0065-0397-05 0065-0397 Alcon Laboratories, Inc. 1 BOTTLE, PLASTIC in 1 CARTON (0065-0397-05) / 5 mL in 1 BOTTLE, PLASTIC October 15, 1975
0065-0397-15 0065-0397 Alcon Laboratories, Inc. 1 BOTTLE, PLASTIC in 1 CARTON (0065-0397-15) / 15 mL in 1 BOTTLE, PLASTIC October 15, 1975
0065-0395 0065-0395 Alcon Laboratories, Inc. — October 15, 1975
0065-0396 0065-0396 Alcon Laboratories, Inc. — October 15, 1975
0065-0397 0065-0397 Alcon Laboratories, Inc. — October 15, 1975

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts

Generated September 25, 2026 · 10 sections on this page.